8-K: LivaNova Appoints Donald Zurbay to Board and Audit Committee
Director Appointment
LivaNova PLC announced the appointment of Donald Zurbay, a seasoned healthcare executive, to its Board of Directors and Audit and Compliance Committee, effective September 4, 2025.
Summary
- LivaNova PLC appointed Donald Zurbay to its Board of Directors and as a member of the Audit and Compliance Committee.
- His term on the Board and Committee begins on September 4, 2025.
- Mr. Zurbay brings over 20 years of leadership experience in healthcare, including roles as President, CEO, and CFO at Patterson Companies, Inc., and CFO at St. Jude Medical, Inc.
- He will receive an annual board retainer of $70,000, an Audit and Compliance Committee annual member fee of $15,000, and an annual service-based restricted stock award valued at $185,000, all prorated until the 2026 Annual General Meeting.
Sentiment
Score: 7
Explanation: The appointment of a highly experienced executive with a strong financial and leadership background is a positive development for corporate governance and strategic direction, indicating a proactive approach to board strengthening.
Positives
- The appointment of a highly experienced executive with a strong background in healthcare, finance, and corporate leadership strengthens the Board.
- Mr. Zurbay's experience as a CFO at two significant companies (Patterson Companies and St. Jude Medical) will enhance financial oversight.
- His prior CEO experience at Patterson Companies provides valuable strategic and operational insights.
- Joining the Audit and Compliance Committee enhances the company's governance and financial reporting integrity.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing beyond the effective date of the director's appointment and the prorated compensation period.
Management Comments
- The Board of Directors appointed Donald Zurbay to the Board and as a member of the Audit and Compliance Committee.
Industry Context
The appointment of a seasoned executive with extensive experience in medical devices and animal health distribution, particularly in financial and leadership roles, aligns with a broader industry trend of strengthening corporate governance and financial oversight. This move is typical for companies seeking to enhance strategic direction and compliance in a complex regulatory environment.
Comparison to Industry Standards
- The appointment of an independent director with a strong financial background, such as a former CFO and CEO, is a common best practice for public companies to ensure robust financial oversight and strategic guidance.
- Mr. Zurbay's experience at St. Jude Medical, a global medical device company, is directly relevant to LivaNova's core business, providing comparable industry expertise.
- His tenure at Patterson Companies, a distributor of dental and animal health products, demonstrates broad healthcare sector knowledge, which is valuable for diversified medical technology firms.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Donald Zurbay | 2025-09-04 | Appointment to strengthen the Board and its Audit and Compliance Committee with an experienced executive. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Committee Appointment | Donald Zurbay was appointed as a member of the Audit and Compliance Committee of the Board. | 2025-09-04 | Enhances the financial expertise and oversight capabilities of the Audit and Compliance Committee, contributing to stronger corporate governance. |
Related Party Transactions
- No arrangements or understandings between Mr. Zurbay and any other person regarding his selection as a director were disclosed.
- Mr. Zurbay has not been a participant in any transaction with the Company since January 1, 2024, nor is he a participant in any proposed transaction required to be disclosed under Item 404(a) of Regulation S-K.
Stakeholder Impact
- Shareholders: Benefit from enhanced corporate governance, financial oversight, and strategic guidance due to the addition of an experienced director.
- Employees: May benefit from stronger leadership and strategic direction at the board level.
- Customers/Suppliers: Indirect positive impact from a more stable and well-governed company.
Next Steps
- Donald Zurbay will serve on the Board and the Audit and Compliance Committee.
- His compensation will be prorated for his service until the 2026 Annual General Meeting.
Key Dates
| Date | Description |
|---|---|
| 2004-03-01 | Donald Zurbay began serving as Vice President and Corporate Controller at St. Jude Medical, Inc. |
| 2012-08-01 | Donald Zurbay began serving as Chief Financial Officer at St. Jude Medical, Inc. |
| 2017-02-01 | Donald Zurbay concluded his role as Chief Financial Officer at St. Jude Medical, Inc. |
| 2018-06-01 | Donald Zurbay began serving as Chief Financial Officer of Patterson Companies, Inc. |
| 2022-10-01 | Donald Zurbay began serving as President, Chief Executive Officer, and board member of Patterson Companies, Inc. |
| 2024-01-01 | Date from which related party transactions involving Mr. Zurbay were reviewed and none were found. |
| 2025-05-01 | Donald Zurbay concluded his role as President, Chief Executive Officer, and board member of Patterson Companies, Inc. |
| 2025-09-03 | LivaNova PLC's Board of Directors appointed Donald Zurbay to the Board and Audit and Compliance Committee. |
| 2025-09-04 | Donald Zurbay's term on the LivaNova PLC Board and Audit and Compliance Committee begins. |
| 2025-09-04 | Date of signing of the 8-K report by Michael Hutchinson. |
| 2026-01-01 | Compensation for Mr. Zurbay is prorated until the 2026 Annual General Meeting. |
Recommendation
holdThis filing details a routine corporate governance update regarding a new director appointment. While the appointment of an experienced executive is a positive for the company's oversight and strategic capabilities, it does not present new financial performance data or strategic shifts that would warrant a change in investment recommendation. The information is primarily qualitative, reinforcing a 'hold' stance for investors awaiting more substantive operational or financial news.
Keywords
LivaNova, LIVN, Board of Directors, Director Appointment, Corporate Governance, Audit Committee, Donald Zurbay, Healthcare, Medical Devices, Executive Appointment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.